Emtricitabine / Tenofovir Disoproxil Oral Tablet — Competitive Intelligence Brief

Emtricitabine / Tenofovir Disoproxil Oral Tablet (Emtricitabine / Tenofovir Disoproxil Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor combination. Area: Infectious Disease / Virology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV-1 reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Emtricitabine / Tenofovir Disoproxil Oral Tablet (Emtricitabine / Tenofovir Disoproxil Oral Tablet) — University of Chicago. Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Emtricitabine / Tenofovir Disoproxil Oral Tablet TARGET	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Rilpivirine (RPV) LA	Rilpivirine (RPV) LA	ViiV Healthcare	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor combination class)

1. ViiV Healthcare · 2 drugs in this class
2. Brigham and Women's Hospital · 1 drug in this class
3. Fundacion IDEAA · 1 drug in this class
4. Janssen Sciences Ireland UC · 1 drug in this class
5. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
6. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
7. University of Chicago · 1 drug in this class
8. University of Washington · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class